Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus

International Journal of Clinical Practice

Volumn 61, Issue 4, 2007, Pages 552-557

  Wang, G ^a   Wang, X ^a   Zhang, Q ^a   Ma, Z ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CHOLESTEROL; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; FEMALE; GENE MUTATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HETEROZYGOTE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 33947362409     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01242.x     Document Type: Article

References (21)

1. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 1999; 42: 1033-49.
2. Way JM, Harrington WW, Brown KK et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001; 142: 1269-77.
3. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-c target genes related to lipid storage in vivo. Diabetes Care 2004; 27: 1660-7.
4. Henderson HE, Kastelein JJ, Zwinderman AH et al. Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. J Lipid Res 1999; 40: 735-43.
5. Groenemeijer BE, Hallman MD, Reymer PW et al. Genetic variant showing a positive interaction with b-blocking agents with a bene-ficial influence on lipoprotein lipase activity, HDL-cholesterol, and triglyceride levels in coronary artery disease patients. The ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. Circulation 1997; 95: 2628-35.
6. Kuivenhoven JA, Groenemeyer BE, Boer JM et al. Ser447stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. Arterioscler Thromb Vasc Biol 1997; 17: 595-9.
7. Ferrannini E, Natali A. Insulin resistance and hypertension: connections with sodium metabolism. Am J Kidney Dis 1993; 21: 37-42.
8. Antonucci T, Whitcomb R, McLain R et al. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997; 20: 188-93.
9. Henriksson KM, Lindblad U, Agren B et al. Associations between body height, body composition and cholesterol levels in middle-aged men. The coronary risk factor study in southern Sweden (CRISS). Eur J Epidemiol 2001; 17: 521-6.
10. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-72.
11. Negro R, Mangieri T, Dazzi D et al. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 2005; 70: 20-5.
12. Fujiwara T, Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci 2000; 67: 2405-16.
13. Liu A, Lee L, Zhan S et al. The S447X polymorphism of the lipoprotein lipase gene is associated with lipoprotein lipid and blood pressure levels in Chinese patients with essential hypertension. J Hypertens 2004; 22: 1503-9.
14. Raji A, Seely EW, Bekins SA et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-8.
15. Ogihara T, Rakugi H, Ikegami H et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316-20.
16. Uchida A, Nakata T, Hatta T et al. Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR. Life Sci 1997; 61: 455-64.
17. Steinberg HO, Tarshoby M, Monestel R et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997; 100: 1230-9.
18. Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605-11.
19. Rosenblatt S, Miskin B, Glazer NB et al. Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-23.
20. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000; 23: 557.
21. Miyazaki Y, Mahankali A, Matsuda M et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-9.